<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523911</url>
  </required_header>
  <id_info>
    <org_study_id>MMC2015-31</org_study_id>
    <nct_id>NCT02523911</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening</brief_title>
  <official_title>Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate Bowel Preparation With and Without Simethicone for Routine Colonoscopy: A Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Medical Center, Des Moines, Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Medical Center, Des Moines, Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate Suprep bowel preparation, with and without the
      anti-gas medication simethicone, in terms of efficacy and patient tolerability in the
      preparation of patients undergoing routine colonoscopy for colorectal cancer screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate sodium sulfate/potassium sulfate/magnesium sulfate (Suprep), with
      and without simethicone, in terms of efficacy and patient tolerability in the preparation of
      patients undergoing routine colonoscopy. Adult ambulatory outpatients who are scheduled for
      elective routine colonoscopy for colorectal cancer screening will be recruited to participate
      in the trial. Patients will be randomized to receive either simethicone or placebo in
      addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep) and
      will receive verbal and written instruction on administration of solutions. During
      colonoscopy, three areas of the colon (right colon, transverse colon, and left colon) will be
      assessed during removal of the colonoscope for overall colon cleansing, presence of bubbles,
      and degree of haziness; this will be scored by a blinded endoscopist. A separate written
      patient questionnaire will be used to assess acceptability and tolerability of the
      preparation, as well as any adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall bowel cleansing</measure>
    <time_frame>During procedure</time_frame>
    <description>To be assessed during removal of the colonoscope during the procedure and blinded endoscopist will score using a written questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>Day prior to and day of colonoscopy</time_frame>
    <description>A written patient questionnaire will be used to assess patient acceptability and tolerability by recording any adverse effects experienced, including nausea, vomiting, headache, insomnia, bloating, abdominal pain, abdominal discomfort, abdominal cramps or any others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients completing the bowel preparation</measure>
    <time_frame>Day prior to and day of colonoscopy</time_frame>
    <description>A written patient questionnaire will be used to assess compliance by asking if the total prescribed volume of solution was ingested and by recording number of evacuations.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of bubbles</measure>
    <time_frame>During procedure</time_frame>
    <description>To be assessed during removal of the colonoscope during the procedure and blinded endoscopist will score using a written questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Degree of haziness</measure>
    <time_frame>During procedure</time_frame>
    <description>To be assessed during removal of the colonoscope during the procedure and blinded endoscopist will score using a written questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Simethicone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone</intervention_name>
    <description>Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.</description>
    <arm_group_label>Simethicone Group</arm_group_label>
    <other_name>Gas-X Infant Drops</other_name>
    <other_name>Infants Gas Relief</other_name>
    <other_name>Infants Simethicone</other_name>
    <other_name>Infants' Mylicon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Inert solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium sulfate/potassium sulfate/magnesium sulfate solution</intervention_name>
    <description>Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation</description>
    <arm_group_label>Simethicone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Suprep Bowel Prep Kit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  Outpatients who require elective colonoscopy for colorectal cancer screening at Iowa
             Endoscopy Center and at University of Florida - Jacksonville

        Exclusion Criteria:

          -  Allergy or hypersensitivity to any constituent of the lavage solution or to
             simethicone

          -  Presence of any contraindication to colonoscopy (i.e. uncontrolled congestive heart
             failure, New York Heart Association classification III-IV, history of myocardial
             infarction within 6 months, coagulopathy)

          -  Massive ascites

          -  Renal insufficiency

          -  Pregnancy

          -  History of colonic surgery

          -  History of anti-flatulence or laxative agent within one week

          -  Refusal/inability to give consent

          -  Patients undergoing colonoscopy for reasons other than colorectal cancer screening

          -  Mentally disabled

          -  Non-English-speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tercio Lopes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa Digestive Disease Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvio de Melo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Health Systems, Jacksonville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tercio Lopes, MD</last_name>
    <email>Limongister@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asim Shuja, MD</last_name>
      <phone>617-842-9989</phone>
      <email>asim.shuja@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Silvio de Melo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Endoscopy Center</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura L Ulmer, DO</last_name>
      <phone>515-473-1762</phone>
      <email>lulmer@mercydesmoines.org</email>
    </contact>
    <contact_backup>
      <last_name>Neha Vohra, DO</last_name>
      <phone>515-443-6391</phone>
      <email>NVohra@mercydesmoines.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laura L Ulmer, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neha Vohra, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tercio Lopes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Valiante F, Bellumat A, De Bona M, De Boni M. Bisacodyl plus split 2-L polyethylene glycol-citrate-simethicone improves quality of bowel preparation before screening colonoscopy. World J Gastroenterol. 2013 Sep 7;19(33):5493-9. doi: 10.3748/wjg.v19.i33.5493.</citation>
    <PMID>24023492</PMID>
  </reference>
  <reference>
    <citation>Gentile M, De Rosa M, Cestaro G, Forestieri P. 2 L PEG plus ascorbic acid versus 4 L PEG plus simethicon for colonoscopy preparation: a randomized single-blind clinical trial. Surg Laparosc Endosc Percutan Tech. 2013 Jun;23(3):276-80. doi: 10.1097/SLE.0b013e31828e389d.</citation>
    <PMID>23751992</PMID>
  </reference>
  <reference>
    <citation>Pontone S, Angelini R, Standoli M, Patrizi G, Culasso F, Pontone P, Redler A. Low-volume plus ascorbic acid vs high-volume plus simethicone bowel preparation before colonoscopy. World J Gastroenterol. 2011 Nov 14;17(42):4689-95. doi: 10.3748/wjg.v17.i42.4689.</citation>
    <PMID>22180711</PMID>
  </reference>
  <reference>
    <citation>Jansen SV, Goedhard JG, Winkens B, van Deursen CT. Preparation before colonoscopy: a randomized controlled trial comparing different regimes. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):897-902. doi: 10.1097/MEG.0b013e32834a3444.</citation>
    <PMID>21900786</PMID>
  </reference>
  <reference>
    <citation>Park JJ, Lee SK, Jang JY, Kim HJ, Kim NH. The effectiveness of simethicone in improving visibility during colonoscopy. Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1321-5.</citation>
    <PMID>19950784</PMID>
  </reference>
  <reference>
    <citation>Tongprasert S, Sobhonslidsuk A, Rattanasiri S. Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol. 2009 Jun 28;15(24):3032-7.</citation>
    <PMID>19554657</PMID>
  </reference>
  <reference>
    <citation>Sudduth RH, DeAngelis S, Sherman KE, McNally PR. The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-bind randomized study. Gastrointest Endosc. 1995 Nov;42(5):413-5.</citation>
    <PMID>8566629</PMID>
  </reference>
  <reference>
    <citation>Lazzaroni M, Petrillo M, Desideri S, Bianchi Porro G. Efficacy and tolerability of polyethylene glycol-electrolyte lavage solution with and without simethicone in the preparation of patients with inflammatory bowel disease for colonoscopy. Aliment Pharmacol Ther. 1993 Dec;7(6):655-9.</citation>
    <PMID>8161673</PMID>
  </reference>
  <reference>
    <citation>Shaver WA, Storms P, Peterson WL. Improvement of oral colonic lavage with supplemental simethicone. Dig Dis Sci. 1988 Feb;33(2):185-8.</citation>
    <PMID>3338367</PMID>
  </reference>
  <reference>
    <citation>Wexner SD, Beck DE, Baron TH, Fanelli RD, Hyman N, Shen B, Wasco KE; American Society of Colon and Rectal Surgeons; American Society for Gastrointestinal Endoscopy; Society of American Gastrointestinal and Endoscopic Surgeons. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc. 2006 Jun;63(7):894-909. Erratum in: Gastrointest Endosc. 2006 Jul;64(1):154.</citation>
    <PMID>16733101</PMID>
  </reference>
  <reference>
    <citation>Chiu HM, Lin JT, Wang HP, Lee YC, Wu MS. The impact of colon preparation timing on colonoscopic detection of colorectal neoplasms--a prospective endoscopist-blinded randomized trial. Am J Gastroenterol. 2006 Dec;101(12):2719-25. Epub 2006 Oct 6.</citation>
    <PMID>17026559</PMID>
  </reference>
  <reference>
    <citation>McNally PR, Maydonovitch CL, Wong RK. The effect of simethicone on colonic visibility after night-prior colonic lavage. A double-blind randomized study. J Clin Gastroenterol. 1989 Dec;11(6):650-2.</citation>
    <PMID>2584664</PMID>
  </reference>
  <reference>
    <citation>McNally PR, Maydonovitch CL, Wong RK. The effectiveness of simethicone in improving visibility during colonoscopy: a double-blind randomized study. Gastrointest Endosc. 1988 May-Jun;34(3):255-8.</citation>
    <PMID>3292345</PMID>
  </reference>
  <reference>
    <citation>Wu L, Cao Y, Liao C, Huang J, Gao F. Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility. Scand J Gastroenterol. 2011 Feb;46(2):227-35. doi: 10.3109/00365521.2010.525714. Epub 2010 Oct 26. Review.</citation>
    <PMID>20977386</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suprep</keyword>
  <keyword>Simethicone</keyword>
  <keyword>Colorectal cancer screening</keyword>
  <keyword>Routine colonoscopy</keyword>
  <keyword>sodium sulfate/potassium sulfate/magnesium sulfate</keyword>
  <keyword>Bowel cleansing</keyword>
  <keyword>Mass screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Sodium sulfate</mesh_term>
    <mesh_term>Cathartics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

